297 related articles for article (PubMed ID: 22520984)
1. Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.
Park SR; Chen A
Hematol Oncol Clin North Am; 2012 Jun; 26(3):649-70, ix. PubMed ID: 22520984
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
He JX; Yang CH; Miao ZH
Acta Pharmacol Sin; 2010 Sep; 31(9):1172-80. PubMed ID: 20676117
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
4. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
Mégnin-Chanet F; Bollet MA; Hall J
Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Lupo B; Trusolino L
Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
[TBL] [Abstract][Full Text] [Related]
6. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.
Annunziata CM; O'Shaughnessy J
Clin Cancer Res; 2010 Sep; 16(18):4517-26. PubMed ID: 20823142
[TBL] [Abstract][Full Text] [Related]
7. Development of PARP inhibitors in oncology.
Rodon J; Iniesta MD; Papadopoulos K
Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
Curtin NJ; Szabo C
Mol Aspects Med; 2013 Dec; 34(6):1217-56. PubMed ID: 23370117
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
12. Role of PARP inhibitors in cancer biology and therapy.
Davar D; Beumer JH; Hamieh L; Tawbi H
Curr Med Chem; 2012; 19(23):3907-21. PubMed ID: 22788767
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in cancer therapy using PARP inhibitors.
Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
[TBL] [Abstract][Full Text] [Related]
14. Advances in using PARP inhibitors to treat cancer.
Kummar S; Chen A; Parchment RE; Kinders RJ; Ji J; Tomaszewski JE; Doroshow JH
BMC Med; 2012 Mar; 10():25. PubMed ID: 22401667
[TBL] [Abstract][Full Text] [Related]
15. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
16. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Sandhu SK; Yap TA; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
[TBL] [Abstract][Full Text] [Related]
17. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
18. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
Ashworth A
J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Feng X; Koh DW
Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.
Basu B; Sandhu SK; de Bono JS
Drugs; 2012 Aug; 72(12):1579-90. PubMed ID: 22834679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]